what exactly does semaglutide do for Weight Loss: How It Works, Comparisons, and More Common GLP-1 Semaglutide Side Effects

Replace every 24 hours for consistent support

This represents a significant breakthrough for Pfizer in the area of oral small molecule GLP-1R agonists and may also bring new treatment options for patients with obesity

At a glance Retatrutide is an investigational weekly injection from Eli Lilly, not yet licensed in the UK It targets three hormone receptors at once GLP-1, GIP and glucagon earning it the nickname "triple G" It reduces appetite, improves blood sugar, and appears to nudge resting energy expenditure upwards Phase 2 trial participants lost an average of around 24% of body weight over 48 weeks at the top dose Side effects mirror existing GLP-1 medications: nausea, mild gut symptoms, reduced appetite Expected UK approval is 18-24 months away pending Phase 3 results and MHRA review The basics: what retatrutide is Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions

Zhou offers these suggestions